Recently, Professor Chen Fangruo, Dean of Antai College of Economics & Management, Dean of Institute of Industry Research, and Dean of Shenzhen Research Institute of Shanghai Jiao Tong University, led a delegation of over 20 professors to visit Grand Shuyang Life Sciences (Chengdu) Co., Ltd. for research and academic exchange.

Recently, 25% human albumin independently developed by Grand Shuyang, a subsidiary of Grand Life Sciences Group Co., Ltd., was officially approved for marketing by the National Medical Products Administration (NMPA). The marketing of this product fills the supply gap for high-concentration human albumin in the Chinese market and provides more efficient and precise treatment protocols for critically ill patients in clinical settings.

As a leading enterprise in China's blood product industry, Grand Shuyang Life Sciences (Chengdu) Co., Ltd. has participated in the CPHI exhibition for consecutive years and demonstrated the outstanding capabilities of Chinese blood product companies to the global market. The Company showcased core products such as human albumin, human immunoglobulin for intravenous injection, and human rabies immunoglobulin, which attracted professional clients from multiple countries in Asia Pacific, the Middle

Recently, the Sichuan Institute of Industry and Information Technology released the "2024 List of Top 100 New Economy Enterprises in Sichuan Province". Grand Shuyang Life Sciences (Chengdu) Co., Ltd. (hereinafter referred to as "Grand Shuyang") was successfully selected as one of the TOP 100 new economy enterprises with its outstanding innovation capabilities, robust market performance, and continuously growing industrial influence.

On January 01, 2025, the "Sunshine Sea" Charity Fund Project, initiated by Grand Shuyang Life Sciences (Chengdu) Co., Ltd. (hereinafter referred to as "Grand Shuyang"), was officially launched at five plasmapheresis centers in Shehong, Santai, Jiange, Guiping, and Pingnan. Over 300 plasma donors attended the launch ceremony. Themed "Sunshine Sea: Love for Plasma Donors", the fund not only recognizes the compassionate act of plasma donation but also provides comprehensive care and support to dono

Recently, the Sichuan Enterprise Confederation announced the list of the 2024 Top 100 Private Enterprises in Sichuan, while the Chengdu Enterprise Confederation unveiled the 2024 list of Top 100 Enterprises in Chengdu. Thanks to its exceptional performance and steady business growth, Grand Shuyang Life Sciences (Chengdu) Co., Ltd. (hereinafter referred to as "Grand Shuyang") has been  listed among one of the Top 100 Manufacturing Enterprises in Sichuan for the third time. Additionally, the compa

From October 08 to 10, 2024, the 33rd CPhI Worldwide 2024 was held grandly at the Milan Convention Center in Italy. As the largest global event in the pharmaceutical raw material industry, CPhI Worldwide has become a pivotal communication hub in the international pharmaceutical community since its inception. It provides participants with an unparalleled platform to showcase the latest products, technologies, and share industry insights, earning the title of the "Heart of the Pharmaceutical Indus

On September 20, 2024, the Second National Volunteer Conference for Plasma Donation and 2024 Plasma-derived Product Industry Development Forum, co-hosted by the China Association for Vaccines and its Plasma-derived Product Branch, were held in Jinggangshan, Ji'an City, Jiangxi Province, China. As a key player in the plasma-derived product industry, Yuanda Shuyang Pharmaceutical actively participated in this prestigious event, demonstrating its exceptional contributions to the sector.

Recently, Yuanda Shuyang human immunoglobulin (pre-filled syringe packaging) was officially approved by National Medical Products Administration, and the drug approval number was: GYZZ S20247006.

Recently, Yuanda Shuyang Pharmaceutical has obtained the GMP certificate issued by the Ministry of Industry and Trade of the Russian Federation. This is the second overseas GMP certificate obtained after the Turkish GMP certificate, indicating that the production and quality management system of Yuanda Shuyang Pharmaceutical's new production base for blood products has been certified by the Pharmaceutical Inspection Co-operation Scheme (PIC/S) and the Eurasian Economic Union (EAEU). This achieve

The Quality Control Center Laboratory (hereinafter referred to as "QIC") of Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. has passed the rigorous evaluation by China National Accreditation Service for Conformity Assessment (hereinafter referred to as "CNAS") and has obtained the certificate of CNAS Laboratory Accreditation, becoming a nationally accredited laboratory. A total of 33 items in three major testing fields of chemistry, microbiology and animal testing of the QIC have been approved.

On March 15, 2024, Tissue Factor Pathway Inhibitor (TFPI) monoclonal antibody KN057 was granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of hemophilia A.